-
公开(公告)号:US20160206596A1
公开(公告)日:2016-07-21
申请号:US14886332
申请日:2015-10-19
发明人: Steven L. McKnight , Andew A. Pieper , Joseph M. Ready , Jef K. De Brabander , Jeffrey M. Zigman
IPC分类号: A61K31/4045 , A61K31/404 , A61K31/422 , A61K31/4188 , A61K31/506 , A61K31/4192 , A61K31/4155 , A61K31/4439 , A61K31/437
CPC分类号: A61K31/4045 , A61K31/403 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/429 , A61K31/437 , A61K31/44 , A61K31/4425 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K31/69 , C07D209/04 , C07D209/08 , C07D209/82 , C07D209/86 , C07D209/88 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/06 , C07D413/06 , C07D413/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07F5/022 , C07F7/0812
摘要: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
摘要翻译: 该技术一般涉及用于刺激神经发生(例如产后神经发生,包括产后海马和下丘脑神经发生)和/或保护神经细胞免于细胞死亡的化合物和方法。 本文公开了各种化合物。 体内活性测试表明,这些化合物可能在神经精神和/或神经变性疾病如精神分裂症,主要抑郁症,双相性精神障碍,正常衰老,癫痫,创伤性脑损伤,创伤后应激障碍,帕金森病,阿尔茨海默病, 唐氏综合征,脊髓小脑性共济失调,肌萎缩性侧索硬化,亨廷顿病,中风,放射治疗,慢性应激,神经活性药物滥用,视网膜变性,脊髓损伤,周围神经损伤,与各种病症相关的生理体重减轻 作为与正常老化,化学疗法等相关的认知衰退。
-
公开(公告)号:US20150057301A1
公开(公告)日:2015-02-26
申请号:US14339742
申请日:2014-07-24
IPC分类号: C07D209/08 , C07D401/06 , C07D413/06 , C07D209/86 , C07D401/12 , C07D403/12 , C07D405/12 , C07D209/88 , C07D471/04
CPC分类号: A61K31/403 , A61K31/00 , A61K31/404 , A61K31/415 , A61K31/4155 , A61K31/4192 , A61K31/422 , A61K31/437 , A61K31/44 , A61K31/4439 , A61K31/506 , A61P25/16 , A61P25/18 , A61P25/28 , C07D209/08 , C07D209/86 , C07D209/88 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D413/06 , C07D471/04
摘要: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protectiong from neuron cell death.
摘要翻译: 本发明一般涉及刺激神经发生(例如,产后神经发生,例如产后海马神经发生)和保护g免受神经元细胞死亡。
-
公开(公告)号:US20140343018A1
公开(公告)日:2014-11-20
申请号:US14339772
申请日:2014-07-24
发明人: Steven L. McKnight , Andew A. Pieper , Joseph M. Ready , Jef K. De Brabander , Jeffrey M. Zigman
IPC分类号: C07D209/04 , C07D401/06 , C07D413/06 , C07D487/04 , C07D403/12 , C07D403/06 , C07F5/02 , C07D209/82 , C07D471/04
CPC分类号: A61K31/4045 , A61K31/403 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/429 , A61K31/437 , A61K31/44 , A61K31/4425 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K31/69 , C07D209/04 , C07D209/08 , C07D209/82 , C07D209/86 , C07D209/88 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/06 , C07D413/06 , C07D413/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07F5/022 , C07F7/0812
摘要: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
摘要翻译: 该技术一般涉及用于刺激神经发生(例如产后神经发生,包括产后海马和下丘脑神经发生)和/或保护神经细胞免于细胞死亡的化合物和方法。 本文公开了各种化合物。 体内活性测试表明,这些化合物可能在神经精神和/或神经变性疾病如精神分裂症,主要抑郁症,双相性精神障碍,正常衰老,癫痫,创伤性脑损伤,创伤后应激障碍,帕金森病,阿尔茨海默病, 唐氏综合征,脊髓小脑性共济失调,肌萎缩性侧索硬化,亨廷顿病,中风,放射治疗,慢性应激,神经活性药物滥用,视网膜变性,脊髓损伤,周围神经损伤,与各种病症相关的生理体重减轻 作为与正常老化,化学疗法等相关的认知衰退。
-
公开(公告)号:US09616048B2
公开(公告)日:2017-04-11
申请号:US14886332
申请日:2015-10-19
发明人: Steven L. McKnight , Andew A. Pieper , Joseph M. Ready , Jef K. De Brabander , Jeffrey M. Zigman
IPC分类号: A61K31/44 , A61K31/403 , A61K31/4439 , A61K31/4045 , C07D209/04 , C07D209/82 , C07D401/06 , C07D413/06 , C07D471/04 , C07D403/12 , C07D403/06 , C07F5/02 , C07D487/04 , A61K31/404 , A61K31/4155 , A61K31/4192 , A61K31/422 , A61K31/437 , A61K31/4425 , A61K31/506 , C07D413/14 , C07D401/12 , C07D403/14 , C07D407/06 , C07D209/88 , C07D405/12 , C07D495/04 , C07D209/08 , C07D209/86 , C07F7/08 , A61K31/4188
CPC分类号: A61K31/4045 , A61K31/403 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/429 , A61K31/437 , A61K31/44 , A61K31/4425 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K31/69 , C07D209/04 , C07D209/08 , C07D209/82 , C07D209/86 , C07D209/88 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/06 , C07D413/06 , C07D413/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07F5/022 , C07F7/0812
摘要: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
-
公开(公告)号:US09162980B2
公开(公告)日:2015-10-20
申请号:US14339772
申请日:2014-07-24
发明人: Steven L. McKnight , Andew A. Pieper , Joseph M. Ready , Jef K. De Brabander , Jeffrey M. Zigman
IPC分类号: A61K31/403 , A61K31/44 , C07D209/04 , C07D209/82 , C07D401/06 , C07D413/06 , C07D471/04 , C07D403/12 , C07D403/06 , C07F5/02 , C07D487/04 , A61K31/4439 , A61K31/404 , A61K31/4155 , A61K31/4192 , A61K31/422 , A61K31/437 , A61K31/4425 , A61K31/506 , C07D413/14 , C07D401/12 , C07D403/14 , C07D407/06 , C07D209/88 , C07D405/12 , C07D495/04 , C07D209/08 , C07D209/86 , C07F7/08
CPC分类号: A61K31/4045 , A61K31/403 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/429 , A61K31/437 , A61K31/44 , A61K31/4425 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K31/69 , C07D209/04 , C07D209/08 , C07D209/82 , C07D209/86 , C07D209/88 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/06 , C07D413/06 , C07D413/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07F5/022 , C07F7/0812
摘要: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
摘要翻译: 该技术一般涉及用于刺激神经发生(例如产后神经发生,包括产后海马和下丘脑神经发生)和/或保护神经细胞免于细胞死亡的化合物和方法。 本文公开了各种化合物。 体内活性测试表明,这些化合物可能在神经精神和/或神经变性疾病如精神分裂症,主要抑郁症,双相性精神障碍,正常衰老,癫痫,创伤性脑损伤,创伤后应激障碍,帕金森病,阿尔茨海默病, 唐氏综合征,脊髓小脑性共济失调,肌萎缩性侧索硬化,亨廷顿病,中风,放射治疗,慢性应激,神经活性药物滥用,视网膜变性,脊髓损伤,周围神经损伤,与各种病症相关的生理体重减轻 作为与正常老化,化学疗法等相关的认知衰退。
-
公开(公告)号:US09156787B2
公开(公告)日:2015-10-13
申请号:US14339742
申请日:2014-07-24
IPC分类号: A61K31/403 , A61K31/44 , C07D209/08 , A61K31/00 , A61K31/415 , A61K31/437 , A61K31/506 , C07D209/86 , C07D401/06 , C07D403/06 , C07D403/12 , C07D405/12 , C07D413/06 , C07D471/04 , C07D209/88 , C07D401/12
CPC分类号: A61K31/403 , A61K31/00 , A61K31/404 , A61K31/415 , A61K31/4155 , A61K31/4192 , A61K31/422 , A61K31/437 , A61K31/44 , A61K31/4439 , A61K31/506 , A61P25/16 , A61P25/18 , A61P25/28 , C07D209/08 , C07D209/86 , C07D209/88 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D413/06 , C07D471/04
摘要: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protection from neuron cell death.
摘要翻译: 本发明一般涉及刺激神经发生(例如,产后神经发生,例如产后海马神经发生)和保护免受神经元细胞死亡。
-
-
-
-
-